2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Clinical Procedures, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Biological Processes, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Immunology, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, B Cell Lymphoma, Indolent Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

3975 Daratumumab-based frontline therapy is associated with improved outcomes in older and frail patients with newly diagnosed multiple myeloma: A propensity-matched real-world study

Okan Cetin, MD, Gizem Teker, MD2, Raphael E. Szalat, MD, PhD3
1 Boston Medical Center – Brighton, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
2 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
3 Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States

Background:

Daratumumab-based regimens are now standard of care in newly diagnosed multiple myeloma (NDMM). However, older and frail patients remain underrepresented in pivotal trials, and comparative real-world data evaluating Dara-RVd, Dara-Rd, and RVd are limited.

Methods:

Older adults aged ≥70 years with NDMM diagnosed in 2020 or later who initiated first-line therapy with Dara-RVd, Dara-Rd, or RVd and did not undergo autologous stem cell transplantation were identified using the TriNetX Research Network. For each comparison (Dara-RVd vs RVd, Dara-RVd vs Dara-Rd, Dara-Rd vs RVd), patients were matched using 1:1 propensity score matching including age, sex, race, comorbidities (diabetes, hypertension, chronic kidney disease, ischemic heart disease, heart failure, COPD), extramedullary plasmacytoma, and baseline laboratory values (LDH, albumin, β2-microglobulin, hemoglobin, creatinine, calcium). A frail subgroup was defined by the presence of ≥1 frailty marker (prior fall, BMI ≤18.5 kg/m², malnutrition, sarcopenia, or dependence on enabling devices) within 1 year before diagnosis. Time to next treatment or death (TTNT/death), overall survival (OS), and 1-year emergency department (ED) visits, ICU admissions, and infections (sepsis, bacterial infections) were evaluated. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards models.

Results:

A total of 592 Dara-RVd, 560 Dara-Rd, and 803 RVd patients were identified before matching.

In the matched comparison of Dara-RVd and RVd (515 per group; median follow-up 12 vs 27 months), Dara-RVd showed longer TTNT/death (median 63 vs 44 months; HR 0.69, 95% CI 0.54–0.88, p=0.002; 1-year TTNT/death event risk 15% vs 23%) and improved OS (median not reached in either group; HR 0.60, 95% CI 0.44–0.82, p=0.001). Within 1 year, Dara-RVd had fewer ED visits (31% vs 38%, p=0.016) and and similar ICU admission and sepsis rates but fewer bacterial infection rates (25% vs 32%, p=0.007). In the frail subgroup (180 per group after matching), Dara-RVd continued to demonstrate superior TTNT/death (median 41 vs 23 months; HR 0.72, 95% CI 0.53–1.00, p=0.045) and OS (median 63 vs 41 months; HR 0.65, 95% CI 0.44–0.96, p=0.030).

In the matched comparison of Dara-Rd and RVd (484 per group; median follow-up 18 vs 26 months), Dara-Rd showed longer TTNT/death (median 60 vs 43 months; HR 0.67, 95% CI 0.54–0.84, p<0.001; 1-year TTNT/death event risk 17% vs 26%) and improved OS (median not reached vs 71 months; HR 0.68, 95% CI 0.52–0.89, p=0.004). Within 1 year, Dara-Rd had fewer ED visits (31% vs 40%, p=0.003) and similar ICU admission, sepsis, and bacterial infection rates. In the frail subgroup (196 per group after matching), Dara-Rd continued to demonstrate superior TTNT/death (median 37 vs 23 months; HR 0.74, 95% CI 0.55–0.98, p=0.036) but not OS (median 60 vs 48 months; HR 0.78, 95% CI 0.56–1.10, p=0.15).

In the matched comparison of Dara-RVd and Dara-Rd (368 per group; median follow-up 12 vs 19 months), outcomes were comparable for TTNT/death (median 61 vs 60 months; HR 1.10, 95% CI 0.81–1.48, p=0.54; 1-year TTNT/death event risk 15% vs 16%) and OS (HR 1.10, 95% CI 0.74–1.63, p=0.64), with similar ED visits, ICU admission, sepsis, and bacterial infection rates. In the frail subgroup (119 per group after matching), Dara-RVd and Dara-Rd remained comparable for TTNT/death (median 35 vs 37 months; HR 1.06, 95% CI 0.69–1.63, p=0.78) and OS (median 63 vs 52 months; HR 0.79, 95% CI 0.46–1.35, p=0.39).

Conclusions:

In this real-world cohort of older patients with NDMM, daratumumab-based frontline therapy (Dara-RVd or Dara-Rd) was associated with longer TTNT/death, OS, and fewer acute-care visits than RVd, while Dara-RVd and Dara-Rd showed similar outcomes. In the frail subgroup, both daratumumab-based regimens maintained a TTNT/death advantage over RVd, although a statistically significant OS benefit was observed only with Dara-RVd. Despite the limitations of this retrospective study, these findings support the effectiveness of daratumumab-based frontline therapy in older and frail patients who remain underrepresented in prospective clinical trials.

Okan Cetin, MD: No relevant conflicts of interest to declare.